close

Myriad Genetics, Inc., a healthcare company, focuses on the development and marketing of novel molecular diagnostic products. It commercializes predictive medicine, personalized medicine, and prognostic medicine products. The company markets BRACAnalys for assessing a woman's risk for breast and ovarian cancer; COLARIS molecular for assessing a person's risk of developing colorectal cancer or uterine cancer; COLARIS AP, a molecular diagnostic product for colon cancer that detects mutations in the APC and MYH genes; and MELARIS, which assesses a persons risk of developing melanoma. It also offers OnDose, a personalized medicine product to measure a patient's exposure to 5-FU chemotherapy; PREZEON that assesses loss of PTEN function in cancer patients; and TheraGuide 5-FU assesses a person's risk of developing a toxic reaction to 5-FU-based chemotherapy. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	24.92
Volume	389742
Volume Avg	570892
52 Week High	25.89
52 Week Low	17.51
PE	20.33
PE (group average)	39
EPS Year	1.22
EPS change Q/Q	23.08%
EPS change Q/Q Yr ago	-5.88%
EPS change Q/Q next Q est	-3.03%
EPS change Y/Y	-7.3%
REV change Q/Q	1.99%
REV change Q/Q Yr ago	12.78%
EPS next Q est	0.33
EPS next Y est	1.46
Divident Annual	0.00
Dividend Yield	0%